Diminished Global Arginine Bioavailability and Increased Arginine Catabolism As Metabolic Profile of Increased Cardiovascular Risk

Overview

Journal J Am Coll Cardiol

Specialty Cardiology & Vascular Diseases

Date 2009 May 30

PMID 19477356

Citations 105

Authors

W H Wilson Tang

Zeneng Wang

Leslie Cho

Danielle M Brennan

Stanley L Hazen

Affiliations

Soon will be listed here.

Abstract

Objectives: We hypothesized that an integrated assessment of arginine with its catabolic products might better predict cardiovascular risks than arginine levels alone.

Background: Arginine is the sole nitrogen source for nitric oxide (NO) synthesis. The major catabolic products of arginine are ornithine and citrulline.

Methods: Plasma levels of free arginine, ornithine, citrulline, and the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) were measured with liquid chromatography coupled with tandem mass spectrometry. We examined the relationship of global arginine bioavailability ratio (GABR) (defined as arginine/[ornithine + citrulline]) versus arginine and its catabolic metabolites to prevalence of significantly obstructive coronary artery disease (CAD) and incidence of major adverse cardiovascular events (MACE) (death, myocardial infarction, stroke) over a 3-year follow-up in 1,010 subjects undergoing elective cardiac catheterization.

Results: Patients with significantly obstructive CAD had significantly lower GABR (median [interquartile range]: 1.06 [0.75 to 1.31] vs. 1.27 [0.96 to 1.73], p < 0.001) and arginine levels [mean: 68 +/- 20 micromol/l vs. 74 +/- 24 micromol/l, p < 0.001) than those without significantly obstructive CAD. After adjusting for Framingham risk score, C-reactive protein, and renal function, lower GABR (but not arginine levels) and higher citrulline levels remained significantly associated with both the prevalence of significantly obstructive CAD (adjusted odds ratio: 3.93, p < 0.001, and 5.98, p < 0.001, respectively) and 3-year risk for the incidence of MACE (adjusted hazard ratio: 1.98, p = 0.025, and 2.40, p = 0.01, respectively) and remained significant after adjusting for ADMA.

Conclusions: GABR might serve as a more comprehensive concept of reduced NO synthetic capacity compared with systemic arginine levels. Diminished GABR and high citrulline levels are associated with both development of significantly obstructive atherosclerotic CAD and heightened long-term risk for MACE.

Citing Articles

Metabolomic Signatures in Adults with Metabolic Syndrome Indicate Preclinical Disruptions in Pathways Associated with High-Density Lipoprotein Cholesterol, Sugar Alcohols.

Lewis K, Stroebel B, Kanaya A, Aouizerat B, Longoria K, Flowers E Res Sq. 2025; .

PMID: 39989952 PMC: 11844646. DOI: 10.21203/rs.3.rs-5989567/v1.

Plasma Levels of Propionylcarnitine Improved Prediction of Heart Failure and All-Cause Mortality in Patients with Stable Coronary Artery Disease.

Lumpuy-Castillo J, Ruperez F, Porto B, Cristobal C, Tarin N, Huelmos A Biomolecules. 2025; 15(1).

PMID: 39858422 PMC: 11764408. DOI: 10.3390/biom15010027.

Replicative Endothelial Cell Senescence May Lead to Endothelial Dysfunction by Increasing the BH2/BH4 Ratio Induced by Oxidative Stress, Reducing BH4 Availability, and Decreasing the Expression of eNOS.

Hernandez-Navarro I, Botana L, Diez-Mata J, Tesoro L, Jimenez-Guirado B, Gonzalez-Cucharero C Int J Mol Sci. 2024; 25(18).

PMID: 39337378 PMC: 11432946. DOI: 10.3390/ijms25189890.

Association between Childhood Overweight and Altered Concentrations of Circulating Amino Acids.

Campos J, Oliveira T, Vitalis O, Pereira J, Nogueira I, Santos G Nutrients. 2024; 16(12).

PMID: 38931197 PMC: 11206240. DOI: 10.3390/nu16121843.

Analysis of differential metabolites in serum metabolomics of patients with aortic dissection.

Gong Y, Li T, Liu Q, Wang X, Deng Z, Cheng L BMC Cardiovasc Disord. 2024; 24(1):226.

PMID: 38664632 PMC: 11044603. DOI: 10.1186/s12872-024-03798-y.

References

Drexler H, Fischell T, Pinto F, Chenzbraun A, Botas J, Cooke J . Effect of L-arginine on coronary endothelial function in cardiac transplant recipients. Relation to vessel wall morphology. Circulation. 1994; 89(4):1615-23. DOI: 10.1161/01.cir.89.4.1615. View

Huynh N, Chin-Dusting J . Amino acids, arginase and nitric oxide in vascular health. Clin Exp Pharmacol Physiol. 2006; 33(1-2):1-8. DOI: 10.1111/j.1440-1681.2006.04316.x. View

Schlaich M, Parnell M, Ahlers B, Finch S, Marshall T, Zhang W . Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation. 2004; 110(24):3680-6. DOI: 10.1161/01.CIR.0000149748.79945.52. View

Tentolouris C, Tousoulis D, Stefanadis C . L-arginine "paradox" in coronary atherosclerosis. Circulation. 2004; 110(7):e71. DOI: 10.1161/01.CIR.0000138900.92435.9A. View

Kaye D, Ahlers B, Autelitano D . In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation. 2000; 102(22):2707-12. DOI: 10.1161/01.cir.102.22.2707. View

Schulman S, Becker L, Kass D, Champion H, Terrin M, Forman S . L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006; 295(1):58-64. DOI: 10.1001/jama.295.1.58. View

Quyyumi A, Dakak N, Diodati J, Gilligan D, Panza J, Cannon 3rd R . Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol. 1997; 30(5):1220-7. DOI: 10.1016/s0735-1097(97)00279-9. View

Bode-Boger S, Scalera F, Ignarro L . The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther. 2007; 114(3):295-306. DOI: 10.1016/j.pharmthera.2007.03.002. View

Tang W, Tong W, Shrestha K, Wang Z, Levison B, Delfraino B . Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J. 2008; 29(20):2506-13. PMC: 2567021. DOI: 10.1093/eurheartj/ehn360. View

10.

Kielstein J, Impraim B, Simmel S, Bode-Boger S, Tsikas D, Frolich J . Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2003; 109(2):172-7. DOI: 10.1161/01.CIR.0000105764.22626.B1. View

11.

Okyay K, Cengel A, Sahinarslan A, Tavil Y, Turkoglu S, Biberoglu G . Plasma asymmetric dimethylarginine and L-arginine levels in patients with cardiac syndrome X. Coron Artery Dis. 2007; 18(7):539-44. DOI: 10.1097/MCA.0b013e3282f08ece. View

12.

Shiraki T, Takamura T, Kajiyama A, Oka T, Saito D . Effect of short-term administration of high dose L-arginine on restenosis after percutaneous transluminal coronary angioplasty. J Cardiol. 2004; 44(1):13-20. View

13.

Boger R, Bode-Boger S, Szuba A, Tsao P, Chan J, Tangphao O . Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998; 98(18):1842-7. DOI: 10.1161/01.cir.98.18.1842. View

14.

Morris Jr S . Arginine metabolism in vascular biology and disease. Vasc Med. 2006; 10 Suppl 1:S83-7. DOI: 10.1177/1358836X0501000112. View

15.

Dumont J, Zureik M, Cottel D, Montaye M, Ducimetiere P, Amouyel P . Association of arginase 1 gene polymorphisms with the risk of myocardial infarction and common carotid intima media thickness. J Med Genet. 2007; 44(8):526-31. PMC: 2597928. DOI: 10.1136/jmg.2006.047449. View

16.

Satriano J . Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines: review article. Amino Acids. 2004; 26(4):321-9. DOI: 10.1007/s00726-004-0078-4. View

17.

Morris C, Poljakovic M, Lavrisha L, Machado L, Kuypers F, Morris Jr S . Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med. 2004; 170(2):148-53. DOI: 10.1164/rccm.200309-1304OC. View

18.

Lee J, Ryu H, Ferrante R, Morris Jr S, Ratan R . Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A. 2003; 100(8):4843-8. PMC: 153643. DOI: 10.1073/pnas.0735876100. View

19.

Wang B, Singer A, Tsao P, Drexler H, Kosek J, Cooke J . Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J Am Coll Cardiol. 1994; 23(2):452-8. DOI: 10.1016/0735-1097(94)90433-2. View

20.

Suschek C, Schnorr O, Hemmrich K, Aust O, Klotz L, Sies H . Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003; 107(20):2607-14. DOI: 10.1161/01.CIR.0000066909.13953.F1. View